; Drug abuse by pregnant women is a problem. About 5% of pregnant women take illicit drugs and up to 20% smoke. Drug abuse is often associated with depression, which is also common in pregnant women. Estimated 5-13% of pregnant women take antidepressant drugs. Two cytochrome P450 enzymes, CYP2D6 and CYP2B6 are responsible for the clearance of majority of common antidepressants and drugs of abuse. Most importantly, CYP2B6 is a major enzyme clearing bupropion, an antidepressant drug also used for smoking cessation and, together with CYP2D6, is responsible for the clearance of many stimulants and opiates such as MDMA and methadone. Despite this clinical importance, the changes in CYP2B6 activity and in bupropion clearance during human pregnancy are not known, whereas increased activity of CYP2D6 during human pregnancy is well documented. In contrast, induction of CYP2B6 in vitro by estrogens has been demonstrated whereas mechansims responsible for CYP2D6 induction are not known. The long term objective of this proposal is to establish the mechanisms that contribute to CYP2D6 induction during pregnancy and determine whether the changes in P450 activity during pregnancy can be predicted from in vitro using CYP2B6 and bupropion as a model system. In our specific aim 1 we will test the hypothesis that increasing estrogen concentrations during human pregnancy induce CYP2B6 activity and expression via 1) using human hepatocytes to predict CYP2B6 induction and bupropion and methadone disposition during pregnancy by estrogens and via ER activation and 2) determining bupropion pharmacokinetics during human gestation in comparison to postpartum. In the second aim we will test the hypothesis that CYP2D6 activity increases during pregnancy due to increased CYP2D6 mRNA and HNF4a and RAR activation via 1) determining the disposition of dextromethorphan during pregnancy in CYP2D6 humanized mice and measuring CYP2D6 mRNA and activity during gestation 2) characterizing the impact of HNF4a and RAR activation in CYP2D6 mRNA and activity in human hepatocytes. We will also establish the in vitro parameters needed for modeling and simulation of MDMA and its metabolite disposition during pregnancy.

Public Health Relevance

Completion of the proposed studies will improve our knowledge on the mechanisms that change drug disposition during pregnancy, and will help us in understanding how the disposition of antidepressants and drugs of abuse changes during pregnancy. This is important because it will allow us to identify drug and gestational stage specific needs for therapeutic adjustments in the clinical care of pregnant women.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA032507-05
Application #
9277439
Study Section
Special Emphasis Panel (ZRG1-DKUS-C)
Project Start
Project End
2019-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
5
Fiscal Year
2017
Total Cost
$181,277
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Domestic Higher Education
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Guo, Yingying; Chu, Xiaoyan; Parrott, Neil J et al. (2018) Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol Ther 104:865-889
Johnson, Emily J; González-Peréz, Vanessa; Tian, Dan-Dan et al. (2018) Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. Drug Metab Dispos 46:1046-1052
Grant, Kimberly S; Petroff, Rebekah; Isoherranen, Nina et al. (2018) Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacol Ther 182:133-151
Wagner, David J; Shireman, Laura M; Ahn, Sojung et al. (2018) Disposition of Methamphetamine and Major Metabolites in Mice: Role of Organic Cation Transporter 3 in Tissue-Selective Accumulation of Para-Hydroxymethamphetamine. Drug Metab Dispos 46:1277-1284
Han, Lyrialle W; Gao, Chunying; Mao, Qingcheng (2018) An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. Expert Opin Drug Metab Toxicol 14:817-829
Patilea-Vrana, Gabriela I; Unadkat, Jashvant D (2018) When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions. Drug Metab Dispos 46:1487-1496
Kumar, Vineet; Yin, Jia; Billington, Sarah et al. (2018) The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance. Drug Metab Dispos 46:1441-1445
Neradugomma, Naveen K; Drafton, Kaitlyn; O'Day, Diana R et al. (2018) Marijuana use differentially affects cannabinoid receptor expression in early gestational human endometrium and placenta. Placenta 66:36-39
Liao, Michael Z; Gao, Chunying; Phillips, Brian R et al. (2018) Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation. Drug Metab Dispos 46:100-108
Wagner, David J; Sager, Jennifer E; Duan, Haichuan et al. (2017) Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters. Drug Metab Dispos 45:770-778

Showing the most recent 10 out of 29 publications